Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: GlobeNewswire
RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 9, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering 33,504 shares and inducement restricted stock unit awards covering 25,128 shares of Mineralys common stock to two new non-executive employees. The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The options will vest over a four-year period, with 25% of the total shares underlying the option vesting on the first anniversary of each award’s vesting commencement date, February 9, 2026, an
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026GlobeNewswire
- Is It Too Late To Consider Mineralys Therapeutics After Its Huge 2025 Share Price Surge [Yahoo! Finance]Yahoo! Finance
- 4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow [Yahoo! Finance]Yahoo! Finance
- Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears [Yahoo! Finance]Yahoo! Finance
MLYS
Earnings
- 11/10/25 - Beat
MLYS
Analyst Actions
- 12/19/25 - Stifel
MLYS
Sec Filings
- 2/13/26 - Form 4
- 2/13/26 - Form SCHEDULE
- 2/13/26 - Form 144
- MLYS's page on the SEC website